63 related articles for article (PubMed ID: 15522650)
1. RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?
Swanton C; Nicke B; Downward J
Lancet Oncol; 2004 Nov; 5(11):653-4. PubMed ID: 15522650
[No Abstract] [Full Text] [Related]
2. Methylation mediated silencing of TMS1 in breast cancer and its potential contribution to docetaxel cytotoxicity.
Gordian E; Ramachandran K; Singal R
Anticancer Res; 2009 Aug; 29(8):3207-10. PubMed ID: 19661336
[TBL] [Abstract][Full Text] [Related]
3. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
[TBL] [Abstract][Full Text] [Related]
4. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.
Sirchia SM; Ren M; Pili R; Sironi E; Somenzi G; Ghidoni R; Toma S; Nicolò G; Sacchi N
Cancer Res; 2002 May; 62(9):2455-61. PubMed ID: 11980632
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
7. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers.
Conway KE; McConnell BB; Bowring CE; Donald CD; Warren ST; Vertino PM
Cancer Res; 2000 Nov; 60(22):6236-42. PubMed ID: 11103776
[TBL] [Abstract][Full Text] [Related]
8. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
9. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.
Leu YW; Yan PS; Fan M; Jin VX; Liu JC; Curran EM; Welshons WV; Wei SH; Davuluri RV; Plass C; Nephew KP; Huang TH
Cancer Res; 2004 Nov; 64(22):8184-92. PubMed ID: 15548683
[TBL] [Abstract][Full Text] [Related]
10. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
[TBL] [Abstract][Full Text] [Related]
11. Reactivating the expression of methylation silenced genes in human cancer.
Karpf AR; Jones DA
Oncogene; 2002 Aug; 21(35):5496-503. PubMed ID: 12154410
[TBL] [Abstract][Full Text] [Related]
12. RNA-directed transcriptional gene silencing in mammals.
Bayne EH; Allshire RC
Trends Genet; 2005 Jul; 21(7):370-3. PubMed ID: 15908035
[TBL] [Abstract][Full Text] [Related]
13. Blocking cancer with RNA interference moves toward the clinic.
Hede K
J Natl Cancer Inst; 2005 May; 97(9):626-8. PubMed ID: 15870429
[No Abstract] [Full Text] [Related]
14. Epigenetic silencing of the sulfotransferase 1A1 gene by hypermethylation in breast tissue.
Kwon MS; Kim SJ; Lee SY; Jeong JH; Lee ES; Kang HS
Oncol Rep; 2006 Jan; 15(1):27-32. PubMed ID: 16328031
[TBL] [Abstract][Full Text] [Related]
15. CpG methylation of the ERalpha and ERbeta genes in breast cancer.
Kim SJ; Kim TW; Lee SY; Park SJ; Kim HS; Chung KW; Lee ES; Kang HS
Int J Mol Med; 2004 Aug; 14(2):289-93. PubMed ID: 15254780
[TBL] [Abstract][Full Text] [Related]
16. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
17. Silencing of retrotransposons in Dictyostelium by DNA methylation and RNAi.
Kuhlmann M; Borisova BE; Kaller M; Larsson P; Stach D; Na J; Eichinger L; Lyko F; Ambros V; Söderbom F; Hammann C; Nellen W
Nucleic Acids Res; 2005; 33(19):6405-17. PubMed ID: 16282589
[TBL] [Abstract][Full Text] [Related]
18. The role of T-fimbrin in the response to DNA damage: silencing of T-fimbrin by small interfering RNA sensitizes human liver cancer cells to DNA-damaging agents.
Ikeda H; Sasaki Y; Kobayashi T; Suzuki H; Mita H; Toyota M; Itoh F; Shinomura Y; Tokino T; Imai K
Int J Oncol; 2005 Oct; 27(4):933-40. PubMed ID: 16142308
[TBL] [Abstract][Full Text] [Related]
19. RPN2 gene confers docetaxel resistance in breast cancer.
Honma K; Iwao-Koizumi K; Takeshita F; Yamamoto Y; Yoshida T; Nishio K; Nagahara S; Kato K; Ochiya T
Nat Med; 2008 Sep; 14(9):939-48. PubMed ID: 18724378
[TBL] [Abstract][Full Text] [Related]
20. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
